Navigation Links
Genetically modified Lactic acid bacteria offers HIV protection

Professor Bharat Ramratnam, Assistant Professor, Brown Medical School is exploring the beneficial properties of Lactic acid bacteria (LAB), which is a good probiotic bacteria which is used for fermentation of curd and yogurt, used as a probiotic drug in treating throat infections and// also as applications in saving fish culture system from pathogenic bacteria.

Cynovirin protein is found to inhibit the binding of HIV virus into the mucous membrane of humans reducing the HIV infectivity. Professor worked on this principle and inserted the Cynovirin DNA in to the LAB through genetic engineering technique of Electroporation through which the Cynovirin DNA is inserted into the LAB and when this LAB is prepared in cream and foamy lotion applications which his applied as a protective shield before sexual intercourse the LAB produces the cynovirin protein which protects in avoiding the attachment of HIV if present in the other partner to this partner.

The researchers also found that these shield also protects from infection of other Sexually transmitted diseases. Researchers have found that this recombinant cream protects infection in experimental animals and a clinical trial for validation of this new cream is necessary before the cream can be used in humans.


'"/>




Page: 1

Related medicine news :

1. Malaria To Be Tackled By Genetically Modified Mosquitoes
2. Genetically modified rice faces strong protests in Asia
3. Genetically modified bacteria to combat HIV
4. Asthma And Obesity Are Genetically Linked
5. Women Are Genetically More Prone To Depression
6. Regulators Object Drug Produced from Genetically Engineered Farm Animals
7. Cocaine Acts As Suppressant Not Stimulant In Genetically Altered Mice
8. Multiple Sclerosis in Genetically Susceptible Twins is Augmented by Northern Environment
9. Humans Genetically More Suited To Being Vegetarians Than Meat-eaters
10. Indian American have Genetically Engineered Edible Cottonseed
11. USDA Gives Go-Ahead to Market Controversial Genetically Engineered Rice, LL601
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... ... , ... Axiad IDS , a leading provider of trusted identities for ... company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor ... proactively address potential cybersecurity threats before they happen. The annual list of ...
(Date:5/23/2017)... ... , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and ... Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations ... today reported on a new study released on May 21, 2017 in the New ...
(Date:5/23/2017)... ... 23, 2017 , ... The Gallery of Cosmetic Surgery, founded ... to announce a new treatment option called Vivace Microneedling. This treatment option is ... body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines a state-of-the-art, best-in-class ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... video chat as a standard feature on its secure clinical communication platform. The ... voice to video depending on the type and urgency of a situation. ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... treatment using the SPEED System™ Orthodontics, with or without a referral, from the ... in El Segundo, CA, who is skilled in providing patients with the custom, ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... MAITLAND, Fla. , May 22, 2017 /PRNewswire/ ... industry as a whole continue to make the ... evidence becomes increasingly important for ensuring positive patient ... Key industry stakeholders are shifting focus away from ... results and effects of long-term specialty drug therapy ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based ... to treat Parkinson,s disease (PD), has enrolled the first patient ... randomized, controlled, multicenter study involving patients with PD and taking ... over a 9-to-12-month period. The first stage is open label ... Participating sites include Denver , ...
Breaking Medicine Technology: